Equities

Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA

Actions
  • Price (EUR)7.88
  • Today's Change0.23 / 3.01%
  • Shares traded1.99k
  • 1 Year change+60.16%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 16:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Key statistics

As of last trade, Newron Pharmaceuticals SpA (NP5:BER) traded at 7.88, 82.41% above the 52 week low of 4.32 set on Nov 24, 2023.
52-week range
Today
4.32Nov 24 202312.40Apr 30 2024
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open7.66
High7.88
Low7.54
Bid7.71
Offer8.06
Previous close7.65
Average volume2.03k
Shares outstanding19.46m
Free float17.45m
P/E (TTM)--
Market cap135.80m CHF
EPS (TTM)-0.9641
CHF
Data delayed at least 15 minutes, as of Nov 21 2024 16:55 GMT.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.